Event Information

Strategic alliances and acquisitions in life sciences are not dead, but they are going through permutations and gyrations in this challenging environment. How has the current market altered the landscape in deal structures?  What are players doing to shift the dynamics in deal structures? What arcane accounting issues lurk beneath the surface that can undermine the logic of business combinations? What are the new deal terms and economics in structuring partnerships with Big Pharma and Big Med Tech companies? Strategic alliances and acquisitions present unusual challenges and opportunities in deal structures, and present particular challenges in accounting and valuation.

Please join us to hear Cooley Godward Kronish partner John Hession, along with other experienced practitioners from the business development and accounting sectors, discuss current issues in FAS 141R, valuation implications on deal structures, creative deal structures for the future to provide liquidity for investors and the spectrum of deal dynamics. This program is by invitation only and is directed at CEOs, CFOs, COOs and VPs of Business Development of life sciences companies.

Panelists:

    John Hession, Partner, Cooley Godward Kronish LLP 
    Mary Trueblood, Biotech CFO, AccountAbility 
    Pam Kelleher, Partner, Ernst & Young 
    Michelle Mittelsteadt, Senior Manager, Ernst & Young

Program Highlights:

REGISTRATION REQUIRED by August 20th. Space is limited and by invitation only. There is no charge to attend this event. Refreshments will be provided.

For more information, please email Christy Kirschenmann or call (212) 479-6163.